Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cediranib and Olaparib vs Bevacizumab in Recurrent Glioblastoma
NCT02974621Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2017
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cediranib and olaparib in glioblastoma (GBM) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival at 6 Months. Started Dec 2017; status: active, not recruiting.
02
Drugs
cediranibolaparib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02974621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02974621.